Synthesis, biological evaluation, 3D-QSAR studies of novel aryl-2H-pyrazole derivatives as telomerase inhibitors. 2013

Yin Luo, and Shuai Zhang, and Ke-Ming Qiu, and Zhi-Jun Liu, and Yu-Shun Yang, and Jie Fu, and Wei-Qing Zhong, and Hai-Liang Zhu
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, P.R. China.

A series of novel aryl-2H-pyrazole derivatives bearing 1,4-benzodioxan or 1,3-benzodioxole moiety were designed as potential telomerase inhibitors to enhance the ability of aryl-2H-pyrazole derivatives to inhibit telomerase, a target of anticancer. The telomerase inhibition tests showed that compound 16A displayed the most potent inhibitory activity with IC(50) value of 0.9 μM for telomerase. The antiproliferative tests showed that compound 16A exhibited high activity against human gastric cancer cell SGC-7901 and human melanoma cell B16-F10 with IC(50) values of 18.07 and 5.34 μM, respectively. Docking simulation showed that compound 16A could bind well with the telomerase active site and act as telomerase inhibitor. 3D-QSAR model was also built to provide more pharmacophore understanding that could be used to design new agents with more potent telomerase inhibitory activity.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D048708 Cell Growth Processes Processes required for CELL ENLARGEMENT and CELL PROLIFERATION. Processes, Cell Growth
D019098 Telomerase An essential ribonucleoprotein reverse transcriptase that adds telomeric DNA to the ends of eukaryotic CHROMOSOMES. Telomerase Catalytic Subunit,Telomerase Reverse Transcriptase,Telomerase Reverse Transcriptase Catalytic Subunit,Catalytic Subunit, Telomerase,Reverse Transcriptase, Telomerase,Subunit, Telomerase Catalytic,Transcriptase, Telomerase Reverse
D021281 Quantitative Structure-Activity Relationship A quantitative prediction of the biological, ecotoxicological or pharmaceutical activity of a molecule. It is based upon structure and activity information gathered from a series of similar compounds. Structure Activity Relationship, Quantitative,3D-QSAR,QSAR,QSPR Modeling,Quantitative Structure Property Relationship,3D QSAR,3D-QSARs,Modeling, QSPR,Quantitative Structure Activity Relationship,Quantitative Structure-Activity Relationships,Relationship, Quantitative Structure-Activity,Relationships, Quantitative Structure-Activity,Structure-Activity Relationship, Quantitative,Structure-Activity Relationships, Quantitative

Related Publications

Yin Luo, and Shuai Zhang, and Ke-Ming Qiu, and Zhi-Jun Liu, and Yu-Shun Yang, and Jie Fu, and Wei-Qing Zhong, and Hai-Liang Zhu
June 2012, Bioorganic & medicinal chemistry,
Yin Luo, and Shuai Zhang, and Ke-Ming Qiu, and Zhi-Jun Liu, and Yu-Shun Yang, and Jie Fu, and Wei-Qing Zhong, and Hai-Liang Zhu
January 2015, Chemical & pharmaceutical bulletin,
Yin Luo, and Shuai Zhang, and Ke-Ming Qiu, and Zhi-Jun Liu, and Yu-Shun Yang, and Jie Fu, and Wei-Qing Zhong, and Hai-Liang Zhu
October 2012, Bioorganic & medicinal chemistry,
Yin Luo, and Shuai Zhang, and Ke-Ming Qiu, and Zhi-Jun Liu, and Yu-Shun Yang, and Jie Fu, and Wei-Qing Zhong, and Hai-Liang Zhu
January 2015, Bioorganic & medicinal chemistry,
Yin Luo, and Shuai Zhang, and Ke-Ming Qiu, and Zhi-Jun Liu, and Yu-Shun Yang, and Jie Fu, and Wei-Qing Zhong, and Hai-Liang Zhu
October 2015, European journal of medicinal chemistry,
Yin Luo, and Shuai Zhang, and Ke-Ming Qiu, and Zhi-Jun Liu, and Yu-Shun Yang, and Jie Fu, and Wei-Qing Zhong, and Hai-Liang Zhu
June 2017, Oncotarget,
Yin Luo, and Shuai Zhang, and Ke-Ming Qiu, and Zhi-Jun Liu, and Yu-Shun Yang, and Jie Fu, and Wei-Qing Zhong, and Hai-Liang Zhu
April 2014, Bioorganic & medicinal chemistry,
Yin Luo, and Shuai Zhang, and Ke-Ming Qiu, and Zhi-Jun Liu, and Yu-Shun Yang, and Jie Fu, and Wei-Qing Zhong, and Hai-Liang Zhu
January 2018, Chemical & pharmaceutical bulletin,
Yin Luo, and Shuai Zhang, and Ke-Ming Qiu, and Zhi-Jun Liu, and Yu-Shun Yang, and Jie Fu, and Wei-Qing Zhong, and Hai-Liang Zhu
November 2022, RSC medicinal chemistry,
Yin Luo, and Shuai Zhang, and Ke-Ming Qiu, and Zhi-Jun Liu, and Yu-Shun Yang, and Jie Fu, and Wei-Qing Zhong, and Hai-Liang Zhu
November 2022, Journal of molecular modeling,
Copied contents to your clipboard!